Ablation performance indicator for electrosurgical devices

Information

  • Patent Grant
  • 9358063
  • Patent Number
    9,358,063
  • Date Filed
    Thursday, February 14, 2008
    16 years ago
  • Date Issued
    Tuesday, June 7, 2016
    8 years ago
Abstract
Ablation performance indicator for electrosurgical devices is described where ablation is typically characterized by the generation of a plasma discharge at the electrode assembly of an electrosurgical probe. When the electrode begins firing, the current waveform assumes a distinct appearance characterized by a spike at the leading edge of each half cycle followed by a lower level for the remaining period of the half cycle. A calculation of the waveform's Crest Factor can be used to determine the state at the electrode, e.g., whether the ablative energy is causing a desirable ablative effect on the electrode. This provides real-time measurements of the RMS and peak current amplitudes along with the Crest Factor and may also be used as limits or inputs to control algorithms or as inputs to indicate whether the device is in its ablative or non-ablative state.
Description
FIELD OF THE INVENTION

The present invention relates to ablation performance indicators for electrosurgical devices. More particularly, the present invention relates to methods and apparatus for determining the ablative state of an electrosurgical device by measuring a wave shape of the current waveform.


BACKGROUND OF THE INVENTION

Electrosurgery typically utilizes the application of high frequency currents to cut or ablate tissue structures, either utilizing a monopolar or bipolar configuration. Monopolar configurations utilize an instrument having a single electrode and rely on external grounding of the patient whereas bipolar configurations utilize both an active and return electrode on the instrument itself for application of a current between the electrodes.


Electrosurgical procedures and techniques are particularly useful in reducing patient bleeding and trauma typically associated with surgical procedures. However, the radio frequency (RF) currents applied by electrosurgical instruments are typically controlled by utilizing control signals indicative of calculated root-mean-square (RMS) voltage and RMS current values. Generally, a current sensing transformer is used to measure the amount of RF current passing through the ablation electrode such that this measured current may be used to derive the RMS current via a signal converter which first squares the RF current input signal and then averages the squared signal over a prescribed period of time. The signal converter then calculates the square root of the average squared value to result in the RMS current. Accordingly, the RMS current signal may take the form of a relatively slowly varying signal compared to a rapidly varying RF current input signal.


Likewise, a voltage sensing transformer may be used to derive the RMS voltage via a RMS voltage converter which squares the RF voltage input signal and then averages it over the same prescribed period of time. The signal converter may then calculate the square root of the average squared voltage values to result in the RMS voltage. These RMS values may be used to control operation of the power supply to maintain the RF output voltage within a desired range or at a constant value or to control the power delivered through the ablation electrode. Such control thus allows for the physician to ablate or coagulate tissue in a controlled manner and may also serve as rudimentary inputs to control algorithms for other instruments.


However, utilization of these RMS values fails to consider the changes in wave shape of the applied voltage and current levels as the device enters different operating modes, particularly in thermal modes (non-ablative) and plasma modes (ablative) thus potentially resulting in the inaccurate application of voltage to the treated tissue.


SUMMARY OF THE INVENTION

Therefore, there is a need for determining the ablative state of an electrosurgical device by measuring a wave shape of the current waveform directly rather than utilizing calculated RMS values to accurately determine whether a device is in an ablative state or a non-ablative state. A system is described to characterize and measure the ablation performance at the electrode of an arthroscopic electrosurgical device. Utilizing RMS values alone in electrosurgical systems to control the delivery of a predetermined level of energy to a tissue region may fail to consider the changes in wave shape as the device enters different operating modes, e.g., thermal mode (non-ablative) and plasma mode (ablative).


As discussed herein, ablation is characterized by the generation of a plasma discharge at the electrode assembly of an electrosurgical probe, the typical voltage waveform is a square waveform and utilization of such plasma to dissociate portions of a target tissue. The measured current waveform may typically approximate a square waveform when the electrosurgical system is operated in the thermal mode, as during an initial period before the plasma mode becomes active, where the current waveform roughly approximates the shape of the square voltage waveform. However, when plasma discharge is initiated and the electrode assembly begins to discharge the current waveform takes on a distinctly different appearance where the current is characterized by a spike at the leading edge of each half cycle followed by a much lower level for the remaining period of the half cycle.


The present system and method preferably discerns a difference between the two wave shapes, e.g., between the signal's initial square waveform (when the system is in the thermal mode) and a spiked waveform (when the system is in the plasma mode) by considering their Crest Factor, C, which for a waveform is defined as C=XPEAK/XRMS, where XPEAK is the peak amplitude of the waveform and XRMS is the RMS or time-averaged value of the waveform over a specified time interval. The Crest Factor may also be defined as the peak-to-average ratio. As a current load is applied such as during an ablative state, the wave shape deviates farther from a square waveform and the Crest Factor increases. For instance, when ablation is active and the system is in the plasma mode, the Crest Factor of the current waveform is several times the value when the ablative state is not active.


A measurement of the Crest Factor can therefore be used to make a determination of the state at the electrode, e.g., whether the applied energy is causing a desirable ablative effect on the electrode. This method may provide real-time measurements of the RMS and peak current amplitudes along with the Crest Factor. Moreover, these parameters may be used as limits or inputs to control algorithms or as inputs into a mechanism to indicate to a user whether the device was in its ablative or non-ablative state.


The present disclosure includes a number of important technical advantages. One technical advantage is the provision of a circuit designed to determine whether an electrode is in an ablative or non-ablative state. Another technical advantage is the provision of an ablation performance indicator on an electrosurgical instrument. Additional advantages will be apparent to those of skill in the art and from the figures, description and claims provided herein.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an exemplary electrosurgical system for an instrument configured to treat various tissue regions.



FIG. 2 illustrates an exemplary electrosurgical probe which generally includes an elongated shaft which may be flexible or rigid, a handle coupled to the proximal end of shaft and a multi-electrode assembly.



FIG. 3 shows a typical square waveform of an applied voltage.



FIG. 4 illustrates an example of a current waveform approximating a square waveform when ablation is inactive and the subsequent spiked waveform resulting from the activation of ablation.



FIG. 5 schematically illustrates an example of an electrical circuit which may be utilized to measure a current waveform of an electrosurgical device.



FIG. 6 shows a chart illustrating a current waveform in the form of a sine wave and the sampling period for obtaining measurements of the waveform.



FIG. 7 illustrates the measured samples providing a reasonable approximation of the waveform.



FIG. 8 shows a flow chart showing a method according to teachings of the present disclosure.





DETAILED DESCRIPTION OF THE INVENTION

As discussed herein, ablation is characterized by the generation of a plasma discharge at the electrode assembly of an electrosurgical probe, the typical voltage waveform is a square waveform and utilization of such plasma to dissociate portions of a target tissue. In other words, as discussed herein, the term ‘ablation’ shall mean the removal, cutting, or resection of target tissue in which a plasma discharge or plasma field developed proximate an active electrode assembly substantially effects such removal, cutting or resection. Further, ablation shall not mean the removal, cutting or resection of tissue where no significant plasma or plasma field is developed and where the primary means for effecting the removal, cutting or resection is by passing current directly through the tissue (e.g. a Bovie device). As ablation is typically characterized by the generation of a plasma discharge at the electrode assembly of an electrosurgical probe, the typical measured current waveform may approximate a square waveform prior to the plasma mode being entered, while the system is still in the thermal mode. However, when plasma discharge is initiated and the electrode assembly begins firing, the current waveform takes on a distinctly different appearance where the current is generally characterized by a spike at the leading edge of each half cycle followed by a substantially lower level for the remaining period of the half cycle.


As described herein, the Crest Factor, C, is preferably used to discern a difference between the two wave shapes, e.g., between the signal's initial square waveform (prior to the initiation of the plasma mode) and a spiked waveform (when the ablation is active). When the electrosurgical system enters the ablative state, the wave shape deviates from a square waveform and the Crest Factor increases. A measurement of the Crest Factor can therefore be used to make a determination of the state at the electrode, e.g., whether the ablative energy is causing a desirable ablative effect on the electrode. This method may preferably provide real-time measurements of the RMS and peak current amplitudes along with the Crest Factor. Moreover, these parameters may be used as limits or inputs to control algorithms or as inputs into a mechanism to indicate to a user whether the device was in its ablative or non-ablative state.


In many electrosurgical procedures, a high frequency voltage difference is applied between the active electrode(s) and one or more return electrode(s) to develop high electric field intensities in the vicinity of the target tissue site. The high electric field intensities lead to electric field induced molecular breakdown of target tissue through molecular dissociation (rather than thermal evaporation or carbonization). This molecular disintegration completely removes the tissue structure, as opposed to dehydrating the tissue material by the removal of liquid from within the cells of the tissue, as is typically the case with electrosurgical desiccation and vaporization.


The high electric field intensities may be generated by applying a high frequency voltage that is sufficient to vaporize an electrically conductive fluid over at least a portion of the active electrode(s) in the region between the distal tip of the active electrode(s) and the target tissue. The electrically conductive fluid may be a gas or liquid, such as isotonic saline, delivered to the target site, or a viscous fluid, such as a gel, that is located at the target site. In the latter embodiment, the active electrode(s) are submersed in the electrically conductive gel during the surgical procedure. Since the vapor layer or vaporized region has relatively high electrical impedance, it minimizes the current flow into the electrically conductive fluid. This ionization, under optimal conditions, induces the discharge of energetic electrons and photons from the vapor layer to the surface of the target tissue. A more detailed description of this cold ablation phenomenon, termed Coblation®, can be found in commonly assigned U.S. Pat. No. 5,683,366 the complete disclosure of which is incorporated herein by reference in its entirety.


The systems and methods for selectively applying electrical energy to a target location within or on a patient's body may be accomplished particularly in procedures where the tissue site is fully or partially flooded or submerged with an electrically conductive fluid, such as during arthroscopic surgery of the knee, shoulder, ankle, hip, elbow, hand, foot, etc. Other tissue regions which may be treated by the system and methods described herein may also include, but are not limited to, prostate tissue, and leiomyomas (fibroids) located within the uterus, gingival tissues and mucosal tissues located in the mouth, tumors, scar tissue, myocardial tissue, collagenous tissue within the eye or epidermal and dermal tissues on the surface of the skin, etc. and may be used in the presence of an electrically conductive gel or where sufficient electrically conductive fluid is available (either delivered to the target site or naturally occurring at the target site). Other procedures which may be performed may also include laminectomy/disketomy procedures for treating herniated disks, decompressive laminectomy for stenosis in the lumbosacral and cervical spine, posterior lumbosacral and cervical spine fusions, treatment of scoliosis associated with vertebral disease, foraminotomies to remove the roof of the intervertebral foramina to relieve nerve root compression, as well as anterior cervical and lumbar diskectomies. Tissue resection within accessible sites of the body that are suitable for electrode loop resection, such as the resection of prostate tissue, leiomyomas (fibroids) located within the uterus, and other diseased tissue within the body, may also be performed.


Other procedures which may be performed where multiple tissue types are present may also include, e.g., the resection and/or ablation of the meniscus and the synovial tissue within a joint during an arthroscopic procedure. It will be appreciated that the systems and methods described herein can be applied equally well to procedures involving other tissues of the body, as well as to other procedures including open procedures, intravascular procedures, urology, laparoscopy, arthroscopy, thoracoscopy or other cardiac procedures, dermatology, orthopedics, gynecology, otorhinolaryngology, spinal and neurologic procedures, oncology, and the like.


The electrosurgical instrument may comprise a shaft or a handpiece having a proximal end and a distal end which supports the one or more active electrodes. The shaft or handpiece may assume a wide variety of configurations, with the primary purpose being to mechanically support the active electrode and permit the treating physician to manipulate the electrodes from a proximal end of the shaft. The shaft may be rigid or flexible, with flexible shafts optionally being combined with a generally rigid external tube for mechanical support. The distal portion of the shaft may comprise a flexible material, such as plastics, malleable stainless steel, etc, so that the physician can mold the shaft and/or distal portion in a desired configuration for a particular application. Flexible shafts may be combined with pull wires, shape memory actuators, and other known mechanisms for effecting selective deflection of the distal end of the shaft to facilitate positioning of the electrode array. The shaft will usually include a plurality of wires or other conductive elements running axially therethrough to permit connection of the electrode array to a connector at the proximal end of the shaft. Thus, the shaft may typically have a length between at least 5 cm and at least 10 cm, more typically being 20 cm or longer for endoscopic procedures. The shaft may typically have a diameter of at least 0.5 mm and frequently in the range of from about 1 mm to 10 mm. Of course, in various procedures, the shaft may have any suitable length and diameter that would facilitate handling by the surgeon.


As mentioned above, a gas or fluid is typically applied to the target tissue region and in some procedures it may also be desirable to retrieve or aspirate the electrically conductive fluid after it has been directed to the target site. In addition, it may be desirable to aspirate small pieces of tissue that are not completely disintegrated by the high frequency energy, air bubbles, or other fluids at the target site, such as blood, mucus, the gaseous products of ablation, etc. Accordingly, the instruments described herein can include a suction lumen in the probe or on another instrument for aspirating fluids from the target site.


Referring to FIG. 1, an exemplary electrosurgical system for a single instrument having multiple electrodes configured to treat varying tissue regions is illustrated in the assembly. As shown, the electrosurgical system may generally comprise an electrosurgical probe 20 connected to a power supply 10 for providing high frequency voltage to the active electrodes. Probe 20 includes a connector housing 44 at its proximal end, which may be either permanently or removably connected to a probe receptacle 32 of a probe cable 22. The proximal portion of cable 22 has a connector 34 to couple probe 20 to power supply 10 to power the one or more electrodes of electrode assembly 42 positioned near or at the distal end of probe 20.


Power supply 10 has an operator controllable voltage level adjustment 38 to change the applied voltage level, which is observable at a voltage level display 40. Power supply 10 may also include one or more foot pedals 24 and a cable 26 which is removably coupled to a receptacle with a cable connector 28. The foot pedal 24 may also include a second pedal (not shown) for remotely adjusting the energy level applied to the active electrodes and a third pedal (also not shown) for switching between an ablation mode and a coagulation mode or for switching to activate between electrodes. In alternative embodiments (not expressly shown) probe 20 may include one or more control switches for activating the ablation or coagulation output and adjusting the energy level applied to the active electrodes. Operation of and configurations for the power supply 10 are described in further detail in U.S. Pat. No. 6,746,447, which is incorporated herein by reference in its entirety.


The voltage applied between the return electrodes and the active electrodes may be at high or radio frequency, typically between about 5 kHz and 20 MHz, usually being between about 30 kHz and 2.5 MHz, preferably being between about 50 kHz and 500 kHz, more preferably less than 350 kHz, and most preferably between about 100 kHz and 200 kHz. The RMS (root mean square) voltage applied will usually be in the range from about 5 volts to 1000 volts, preferably being in the range from about 10 volts to 500 volts depending on the active electrode size, the operating frequency and the operation mode of the particular procedure or desired effect on the tissue (i.e., contraction, coagulation or ablation). Typically, the peak-to-peak voltage will be in the range of 10 to 2000 volts, preferably in the range of 20 to 1200 volts and more preferably in the range of about 40 to 800 volts (again, depending on the electrode size, the operating frequency and the operation mode).


The power source may be current limited or otherwise controlled so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. In one variation, current limiting inductors are placed in series with each independent active electrode, where the inductance of the inductor is in the range of 10 uH to 50,000 uH, depending on the electrical properties of the target tissue, the desired tissue heating rate and the operating frequency. Alternatively, capacitor-inductor (LC) circuit structures may be employed, as described previously in PCT application WO 94/026228, which is incorporated herein by reference in its entirety.


Additionally, current limiting resistors may be selected. These resistors will have a large positive temperature coefficient of resistance so that, as the current level begins to rise for any individual active electrode in contact with a low resistance medium (e.g., saline irrigant or conductive gel), the resistance of the current limiting resistor increases significantly, thereby minimizing the power delivery from the active electrode into the low resistance medium (e.g., saline irrigant or conductive gel).



FIG. 2 illustrates an exemplary electrosurgical probe 20 which generally includes an elongate shaft 50 which may be flexible or rigid, a handle 52 coupled to the proximal end of shaft 50 and an electrode assembly 54, described in further detail below, coupled to the distal end of shaft 50. Shaft 50 may comprise an electrically conducting material, such as metal, which may be selected from the group consisting of, e.g., tungsten, stainless steel alloys, platinum or its alloys, titanium or its alloys, molybdenum or its alloys, and nickel or its alloys. Shaft 50 also includes an electrically insulating jacket 56, which is typically formed as one or more electrically insulating sheaths or coatings, such as polytetrafluoroethylene, polyimide, and the like. The provision of the electrically insulating jacket over the shaft prevents direct electrical contact between these conductive elements and any adjacent body structure or the user One or more lumens (not expressly shown) may be formed within or along shaft 50 and terminate in openings at the distal end of shaft 50 to deliver fluid or provide suction proximate electrode assembly 54. Such lumens may also pass through handle 52 to allow for fluid communication with a suitable fluid source or suction/vacuum source.


Handle 52 typically comprises a plastic material that is easily molded into a suitable shape for handling by the surgeon. Moreover, the distal portion of shaft 50 may be bent to improve access to the operative site of the tissue being treated. In alternative embodiments, the distal portion of shaft 50 comprises a flexible material which can be deflected relative to the longitudinal axis of the shaft. Such deflection may be selectively induced by mechanical tension of a pull wire, for example, or by a shape memory wire that expands or contracts by externally applied temperature changes. A more complete description of this embodiment can be found in PCT application WO 94/026228, which has been incorporated by reference above.


The bend in the distal portion of shaft 50 is particularly advantageous in arthroscopic treatment of joint tissue as it allows the surgeon to reach the target tissue within the joint as the shaft 50 extends through a cannula or portal. Of course, it will be recognized that the shaft may have different angles depending on a particular treatment application. For example, a shaft having a 90° bend angle may be particularly useful for accessing tissue located in the back portion of a joint compartment and a shaft having a 10° to 30° bend angle may be useful for accessing tissue near or in the front portion of the joint compartment.


Regardless of the bend angle, an electrode assembly having multiple, e.g., two or more, electrodes disposed near or at the distal end of shaft 50 may be utilized. One difficulty in designing electrosurgical devices with relatively large active electrodes is that a relatively high level of RF energy is delivered before ablative effects are activated at the electrodes. However, once the ablative effects are activated, the load impedance increases and the power delivery to the tissue decreases. In some embodiments a multi-electrode assembly may be configured to more effectively deliver the energy to a tissue region of interest, for instance, less energy may be required than if a single electrode with the same overall effective surface area were used. In such embodiments the multiple electrodes may effectively serve to “diffuse” the same amount of energy over a larger area.


Power supply 10 as described in the present system above as well as other electrosurgical systems may be controlled to deliver a predetermined level of energy to a tissue region to be treated. This may utilize limiting the applied current or voltage so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. Utilizing RMS values alone fails to consider the changes in wave shape as the device enters different operating modes, particularly in thermal mode (non-ablative) and plasma mode (ablative).


Probe 20 further includes performance indicator 55. Performance indicator 55 may include one or more LEDs or similar indicators in electrical communication with circuit 90. As circuit 90 determines that probe 20 is an ablative or non-ablative state based on Crest Factor C, indicator 55 may be illuminated to provide the user a visual indication of whether an ablative or non-ablative state is detected. In an alternative embodiment an indicator (not expressly shown) may be disposed within power supply 10 either in addition to or in place of indicator 55. Additionally, such an indicator provided in the power supply may also provide an audible tone or similar audible signal to indicate the detected state to the user.


As discussed herein, ablation is typically characterized by the generation of a plasma discharge at the electrode assembly 54 of the electrosurgical probe 20. The typical voltage waveform is illustrated in plot 60 which shows square waveform 62 in FIG. 3. The measured current waveform 70, as illustrated in FIG. 4, illustrates an initial square waveform 76 when the electrosurgical system is operating in the thermal mode, as during initial period 72. The square current waveform 76 roughly approximates the shape of the voltage waveform 62 illustrated above as the applied load is purely resistive. However, when plasma discharge is initiated and electrode assembly 54 begins firing, the current waveform takes on a distinctly different appearance, as indicated during the period of active ablation 74. During this period of active ablation, the current is characterized by a spike 78 at the leading edge of each half cycle followed by a much lower level 80 for the remaining period of the half cycle.


As described herein, waveform 70 is preferably analyzed to discern a difference between the two wave shapes, e.g., between the signal's initial square waveform 76 (when the system is in the thermal mode 72) and spiked waveform 78 (when the system is in the plasma mode 74). The difference between the two waveforms may be discerned by considering their Crest Factor, C, which for a waveform is defined as:









C
=


X
PEAK


X

R





MS







(
1
)








where XPEAK is the peak amplitude of the waveform and XRMS is the RMS or time-averaged value of the waveform over a specified time interval. The Crest Factor is sometimes also defined as the peak-to-average ratio. When the system is in the thermal mode during an initial non-ablative period 72, the current waveform is square and the Crest Factor is 1 where the peak amplitude and RMS values are equal, e.g., square waveform 76. Once the system begins operating in the plasma mode, such as during ablative state 74, the wave shape deviates farther from a square waveform and the Crest Factor increases, e.g., spiked waveform 78. For instance, when ablation is active 74 the Crest Factor of the current waveform is several times the value when it is not active 72.


When an electrosurgical device, e.g., an arthroscopic ablation instrument, enters an ablative state the waveform is typically characterized by a relatively high leading edge or spike 78, followed by a much lower level 80 for the remaining half cycle resulting in a high Crest Factor since its peak is much higher than its RMS value. A measurement of the Crest Factor can therefore be used to make a determination of the state at the electrode, e.g., whether the ablative energy is causing a desirable ablative effect (for example, creating a plasma) proximate the electrode. This method may provide real-time measurements of the RMS and peak current amplitudes along with the Crest Factor. Moreover, these parameters may be used as limits or inputs to control algorithms or as inputs into a mechanism to indicate to a user whether the device was in its ablative or non-ablative state.


An example for measuring current loads and for determining an instrument's ablative state is shown in the schematic illustration of circuit 90 in FIG. 5. As illustrated, an electrode circuit 92 powered by power supply 94, e.g., RF generator, may supply power to an electrode assembly which functions as an RF load 96. The electrode assembly is preferably disposed within an electrosurgical instrument as described above for ablating tissue regions of interest. A sensing circuit 98 may be in electrical communication with the electrode circuit 92 via a current sensing transformer 102 which may be utilized to allow direct measurements of the RF current waveform from circuit 92. The measured current may be converted to a digital signal by implementing a high-speed digital signal processing (DSP) and/or microcontroller (MCU) device 100 which is part of the sensing circuit 98.


The current measurement detected from transformer 102 may be input to a high-speed analog-to-digital converter (ADC) input on DSP 100, which may utilize this input signal to calculate the RMS and peak values of the waveform as well as to calculate the Crest Factor of the waveform. An example of a suitable DSP may include the Microchip dsPIC30 line of devices which provides a 10-bit converter resolution to represent the measured analog sample. Moreover, the Microchip dsPIC30 is widely available commercially and typically includes on-board ADC converters that operate at a throughput rate of up to 2 MSPS. A number of manufacturers also make DSP/MCU devices with similar capabilities that may be utilized. The example of the Microchip dsPIC30 is provided only to be illustrative of the type of DSP which may be utilized to process the various calculations and is not intended to be limiting in any manner.


With the sensed signals detected by transformer 102 input to the ADC input on DSP 100, several resistors 104 (e.g., R1, R2, and R3) connected to transformer 102 and also connected in series with DSP 100 may be included to provide sufficient resolution of the current waveform detected by transformer 102 and so that it is bounded by VSS (ground) and VDD (supply voltage) as shown in DSP 100 in the schematic illustration. Also, a sufficient DC bias may be added to the AC current waveform by the application of +5 VDC in communication with the resistors 104. If R1 and R2 were equal in the sensing circuit 98, the DC bias added to the current waveform may be about 2.5 VDC.


With the electrode circuit 92 and sensing circuit 98 in electrical communication, the RMS value of the measured current may be computed based upon a predetermined number of samples, N, measured by current sensing transformer 102. Accordingly, the RMS value of N samples of a signal can be computed using the expression:










X

RM





S


=




X
1
2

+

X
2
2

+

X
3
2

+

+

X
N
2


N






(
2
)







The high-speed ADC on DSP 100 can be run at up to, e.g., 2 MSPS, for input sampling. The calculated RMS value may be fairly accurately calculated when, e.g., N=256 samples, are included in the function. The current waveform may be sampled by sensing circuit 98 at a frequency of:










f
SAMPLE

=


f
SIGNAL

(

1
-

1
N


)





(
3
)








where N=256 such that representative samples are collected over approximately 256 cycles. The value of fSAMPLE represents the sampling frequency by sensing circuit 98 while fSIGNAL represents the frequency of the measured signal through electrode circuit 92.


This is shown in the graph 110 of FIG. 6 which illustrates the signal wavelength 114, λSIGNAL, and “wavelength” of the sampling rate 116, λSAMPLE, where the current signal through electrode circuit 92 is represented by sine wave 112 and the measured values 118 of X1, X2, . . . , X8 are measured at the frequency, fSAMPLE, by sensing circuit 98. Considered together, this representative measurement of, e.g., eight samples (X1, X2, . . . , X8), can provide a reasonable approximation of the wave shape, as shown in the plot 120 of FIG. 7. The representative measurement of eight samples is shown only for illustrative purposes and the number of samples may vary depending upon the sampling frequency and the sampling time.


With the N number of samples, e.g., N=256, a first step in the data processing is to subtract the DC bias from each of the N samples. For a 10-bit value, this would result in a signed value between −511 and 512. After the DC bias is removed, each of the samples may be scanned with the absolute value calculated and the maximum value identified and retained, which represents XPEAK. DSP 100 may include at least two 40-bit accumulators and built in functions to perform algebraic operations which enable calculation of the numerator of the XPEAK value.


After the values of the samples, N, are squared and accumulated, they are divided by the N samples, e.g., 256 samples, and the square root of the resulting value is calculated to provide XRMS according to equation (2) above. With XPEAK and XRMS calculated, the Crest Factor, C, of the waveform may be calculated according to equation (1) above. This may allow for all three values: XPEAK, XRMS, and C to be reported via a user interface as an absolute limit or they may be used as input to either an RF or other control algorithm. For example, an algorithm may advantageously be used to regulate the vacuum or suction flow through the aspiration lumen in the device in order to allow the system to continuously remain in the ablative or plasma mode.


The Crest Factor, C, also may be used as an input for an indicator to determine whether the electrosurgical device is in a plasma mode (ablative) or a thermal mode (non-ablative), based on whether C has exceeded a specified threshold.


Now referring to FIG. 8, a flow diagram 150 showing a method according to the present disclosure is shown. The method 150 begins 152 as an electrosurgical device is used and the current waveform at the device or at the associated generator is measured 154. Next the peak amplitude and time-averaged amplitude of the current waveform is calculated 156. The peak-to-average ratio is then calculated 158 based upon the peak and time-averaged amplitudes determined in step 156. This peak-to-average ratio may then preferably be used to determine whether the electrosurgical is in an ablative mode or a non-ablative mode 160. When it is determined that the device is operating in an ablative mode, an indicator (such as indicator 55 shown in FIG. 2) may be illuminated or otherwise activated 162.


Alternatively, the indicator may be activated instead when a non-ablative mode or state is detected. In yet another embodiment, two or more indicators may be provided and each indicator may be activated to signal the detection of a selected mode of operation at the electrode. In still other alternative embodiments, the associated generator may include a visual or audible indicator in order to indicate the detected mode of operation of the electrode. In other embodiments, the determination that the device is in an ablative mode may be used as an input in a control algorithm as discussed above. In a preferred embodiment, steps 154, 156, 158, 160 and 162 may be continuously cycled while the electrosurgical device is activated, providing a real time or substantially real time indication of the ablative (or non-ablative) state of the electrosurgical device. The method ends at 164 when the electrosurgical device is inactive.


Other modifications and variations can be made to the disclosed embodiments without departing from the subject invention. For example, other uses or applications in characterizing waveforms are possible. Similarly, numerous other methods of controlling or characterizing instruments or otherwise treating tissue using electrosurgical probes will be apparent to the skilled artisan. Moreover, the instruments and methods described herein may be utilized in instruments for various regions of the body (e.g., shoulder, knee, etc.) and for other tissue treatment procedures (e.g., chondroplasty, menectomy, etc.). Thus, while the exemplary embodiments have been described in detail, by way of example and for clarity of understanding, a variety of changes, adaptations, and modifications will be obvious to those of skill in the art. Therefore, the scope of the present invention is limited solely by the appended claims.

Claims
  • 1. A method of determining a mode of an electrosurgical instrument, comprising: supplying a first high frequency square waveform voltage input to the instrument;sensing a measured current waveform generated at an electrode of the instrument;determining a peak amplitude and a time-averaged amplitude of the measured current waveform;calculating a peak-to-average ratio based upon the peak and the time-averaged amplitudes; anddetermining whether the electrode of the instrument is in an ablative mode or non-ablative mode based upon the calculated peak-to-average ratio, wherein while supplying the first high frequency voltage input, the calculated peak-to-average ratio of the measured current waveform increases significantly when the instrument is in the ablative mode as compared to the non-ablative mode and wherein during the ablative mode a plasma is generated at the electrode.
  • 2. The method of claim 1 further comprising activating an indicator disposed on the instrument when the instrument is determined to be operating in the ablative mode.
  • 3. The method of claim 1 wherein the sensing of the measured current waveform comprises sensing the measured current waveform via a current sensing transformer.
  • 4. The method of claim 3 further comprising adding a DC bias to the measured current waveform.
  • 5. The method of claim 4 wherein calculating further comprises removing a DC bias from the measured current waveform.
  • 6. The method of claim 1 wherein the calculating comprises calculating via a digital signal processor in electrical communication with the instrument.
  • 7. The method of claim 1 further comprising sampling the measured current waveform at some frequency slightly below the fundamental frequency of the measured current waveform so that the sampling is performed over a multiple number of successive cycles of the measured current waveform.
  • 8. The method of claim 1 wherein the measured current waveform is characterized by a spike at a leading edge of a half cycle followed by a relatively lower level for a remainder of the half cycle when the instrument is in the ablative mode.
  • 9. The method of claim 1 wherein the peak-to-average ratio of the measured current waveform increases as an ablative load is applied by the instrument.
  • 10. The method of claim 1 further comprising utilizing the peak-to-average ratio as an input for a control algorithm of the instrument.
  • 11. The method of claim 1 wherein the peak-to-average ratio approximates the value 1 when in non-ablative mode.
  • 12. The method of claim 1 wherein the measured current waveform is characterized by a square waveform when in non-ablative mode.
  • 13. The method of claim 1 wherein during the step of supplying the first high frequency voltage input, the electrode of the instrument is initially in the non-ablative mode and transitions to the ablative mode as a plasma discharge is initiated.
  • 14. The method of claim 1 wherein when the electrode is the non-ablative mode, the measured current waveform and the voltage waveform are similar in shape, and when the electrode is in the ablative mode, the measured current waveform and the voltage waveform look significantly dissimilar in shape.
  • 15. A method of determining a state of an electrosurgical instrument, comprising: supplying a fixed high frequency square waveform voltage input to the instrument;sensing a measured current waveform generated at an electrode assembly of the instrument;determining a peak amplitude and a time-averaged amplitude of the measured current waveform;calculating a peak-to-average ratio based upon the peak and the time-averaged amplitudes; anddetermining whether the electrode assembly is generating a plasma, based upon the calculated peak-to-average ratio, wherein the initiation of the plasma at the electrode assembly causes the calculated peak-to-average ratio to increase significantly compared to when no plasma is present.
  • 16. A method of determining a tissue effect mode of an electrosurgical instrument, comprising: supplying a high frequency square waveform voltage input to the instrument;sensing a measured current waveform generated at an electrode of the instrument;determining a peak amplitude and a time-averaged amplitude of the measured current waveform;calculating a peak-to-average ratio based upon the peak and the time-averaged amplitude; andwherein during the supplying step, the tissue effect mode at the electrode may transition between an ablative mode and non-ablative mode while continuing to maintain the high frequency square waveform voltage input; the tissue effect mode detected based upon the calculated peak-to-average ratio wherein the calculated peak-to-average ratio is significantly higher when the instrument is in the ablative mode as compared to the non-ablative mode.
US Referenced Citations (537)
Number Name Date Kind
2050904 Trice Apr 1936 A
2056377 Wappler Oct 1939 A
2611365 Rubens Sep 1952 A
3434476 Shaw et al. Mar 1969 A
3633425 Sanford Jan 1972 A
3707149 Hao et al. Dec 1972 A
3718617 Royal Feb 1973 A
3815604 O'Malley et al. Jun 1974 A
3828780 Morrison, Jr. et al. Aug 1974 A
3901242 Storz Aug 1975 A
3920021 Hiltebrandt Nov 1975 A
3939839 Curtiss Feb 1976 A
3963030 Newton Jun 1976 A
3964487 Judson Jun 1976 A
3970088 Morrison Jul 1976 A
4033351 Hetzel Jul 1977 A
4040426 Morrison, Jr. Aug 1977 A
4043342 Morrison, Jr. Aug 1977 A
4074718 Morrison, Jr. Feb 1978 A
4092986 Schneiderman Jun 1978 A
D249549 Pike Sep 1978 S
4114623 Meinke et al. Sep 1978 A
4116198 Roos Sep 1978 A
4181131 Ogiu Jan 1980 A
4184492 Meinke et al. Jan 1980 A
4202337 Hren et al. May 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4232676 Herczog Nov 1980 A
4240441 Khalil Dec 1980 A
4248231 Herczog et al. Feb 1981 A
4326529 Doss et al. Apr 1982 A
4346715 Gammell Aug 1982 A
4363324 Kusserow Dec 1982 A
4378801 Oosten Apr 1983 A
4381007 Doss Apr 1983 A
4418692 Guay Dec 1983 A
4474179 Koch Oct 1984 A
4476862 Pao Oct 1984 A
4509532 DeVries Apr 1985 A
4532924 Auth et al. Aug 1985 A
4548207 Reimels Oct 1985 A
4567890 Ohta et al. Feb 1986 A
4572206 Geddes et al. Feb 1986 A
4580557 Hertzmann Apr 1986 A
4587975 Salo et al. May 1986 A
4590934 Malis et al. May 1986 A
4593691 Lindstrom et al. Jun 1986 A
4658817 Hardy Apr 1987 A
4660571 Hess et al. Apr 1987 A
4674499 Pao Jun 1987 A
4682596 Bales et al. Jul 1987 A
4706667 Roos Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4727874 Bowers et al. Mar 1988 A
4750902 Wuchinich et al. Jun 1988 A
4765331 Petruzzi et al. Aug 1988 A
4785823 Eggers et al. Nov 1988 A
4805616 Pao Feb 1989 A
4823791 D'Amelio et al. Apr 1989 A
4832048 Cohen May 1989 A
4846179 O'Connor Jul 1989 A
4860752 Turner Aug 1989 A
4907589 Cosman Mar 1990 A
4920978 Colvin May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936301 Rexroth et al. Jun 1990 A
4943290 Rexroth et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4967765 Turner et al. Nov 1990 A
4976711 Parins et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5007908 Rydell Apr 1991 A
5009656 Reimels Apr 1991 A
5026387 Thomas Jun 1991 A
5035696 Rydell Jul 1991 A
5047026 Rydell Sep 1991 A
5047027 Rydell Sep 1991 A
5057105 Malone et al. Oct 1991 A
5057106 Kasevich et al. Oct 1991 A
5057743 Krasko et al. Oct 1991 A
5078717 Parins et al. Jan 1992 A
5080660 Buelna Jan 1992 A
5083565 Parins Jan 1992 A
5084044 Quint Jan 1992 A
5085659 Rydell Feb 1992 A
5086401 Glassman et al. Feb 1992 A
5088997 Delahuerga et al. Feb 1992 A
5092339 Geddes et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5099840 Goble Mar 1992 A
5102410 Dressel Apr 1992 A
5108391 Flachenecker et al. Apr 1992 A
RE33925 Bales et al. May 1992 E
5112330 Nishigaki et al. May 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5156151 Imran Oct 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5174304 Latina et al. Dec 1992 A
5178620 Eggers et al. Jan 1993 A
5183338 Wickersheim et al. Feb 1993 A
5190517 Zieve et al. Mar 1993 A
5192280 Parins Mar 1993 A
5195959 Smith Mar 1993 A
5197466 Marchosky et al. Mar 1993 A
5197963 Parins Mar 1993 A
5207675 Canady May 1993 A
5217457 Delahuerga et al. Jun 1993 A
5217459 Kamerling Jun 1993 A
5249585 Turner et al. Oct 1993 A
5255980 Thomas et al. Oct 1993 A
5261410 Alfano et al. Nov 1993 A
5267994 Gentelia et al. Dec 1993 A
5267997 Farin et al. Dec 1993 A
5273524 Fox et al. Dec 1993 A
5277201 Stern Jan 1994 A
5281216 Klicek Jan 1994 A
5281218 Imran Jan 1994 A
5282799 Rydell Feb 1994 A
5290282 Casscells Mar 1994 A
5300069 Hunsberger et al. Apr 1994 A
5306238 Fleenor Apr 1994 A
5312400 Bales et al. May 1994 A
5314406 Arias et al. May 1994 A
5318563 Malis et al. Jun 1994 A
5324254 Phillips Jun 1994 A
5330470 Hagen Jul 1994 A
5334140 Phillips Aug 1994 A
5334183 Wuchinich Aug 1994 A
5334193 Nardella Aug 1994 A
5336172 Bales et al. Aug 1994 A
5336220 Ryan et al. Aug 1994 A
5336443 Odashima Aug 1994 A
5342357 Nardella Aug 1994 A
5348026 Davidson Sep 1994 A
5348554 Imran et al. Sep 1994 A
5354291 Bales et al. Oct 1994 A
5366443 Eggers et al. Nov 1994 A
5370675 Edwards et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5375588 Yoon Dec 1994 A
5380277 Phillips Jan 1995 A
5380316 Aita Jan 1995 A
5383874 Jackson et al. Jan 1995 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5389096 Aita Feb 1995 A
5395312 Desai Mar 1995 A
5400267 Denen et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5417687 Nardella et al. May 1995 A
5419767 Eggers et al. May 1995 A
5423810 Goble et al. Jun 1995 A
5423882 Jackman et al. Jun 1995 A
5436566 Thompson et al. Jul 1995 A
5437662 Nardella Aug 1995 A
5438302 Goble Aug 1995 A
5441499 Fritzsch Aug 1995 A
5449356 Walbrink et al. Sep 1995 A
5451224 Goble et al. Sep 1995 A
5454809 Janssen Oct 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5472443 Cordis et al. Dec 1995 A
5472444 Hueber et al. Dec 1995 A
5486161 Lax et al. Jan 1996 A
5496312 Klicek Mar 1996 A
5496314 Eggers Mar 1996 A
5496317 Goble et al. Mar 1996 A
5505730 Edwards et al. Apr 1996 A
5514130 Baker May 1996 A
5540683 Ichikawa et al. Jul 1996 A
5542915 Edwards et al. Aug 1996 A
5554152 Aita Sep 1996 A
5556397 Long et al. Sep 1996 A
5562703 Desai Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571100 Goble et al. Nov 1996 A
5573533 Strul Nov 1996 A
5584872 LaFontaine et al. Dec 1996 A
5588960 Edwards et al. Dec 1996 A
5599350 Schulze et al. Feb 1997 A
5609151 Mulier et al. Mar 1997 A
5609573 Sandock Mar 1997 A
5633578 Eggers et al. May 1997 A
5643304 Schechter et al. Jul 1997 A
5647869 Goble et al. Jul 1997 A
5658278 Imran et al. Aug 1997 A
5660567 Nierlich et al. Aug 1997 A
5662680 Desai Sep 1997 A
5676693 LaFontaine et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5697925 Taylor Dec 1997 A
5697927 Imran et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5715817 Stevens-Wright et al. Feb 1998 A
5722975 Edwards et al. Mar 1998 A
5725524 Mulier et al. Mar 1998 A
5749869 Lindenmeier et al. May 1998 A
5749871 Hood et al. May 1998 A
5749914 Janssen May 1998 A
5755753 Knowlton May 1998 A
5766153 Eggers et al. Jun 1998 A
5769847 Panescu et al. Jun 1998 A
5785705 Baker Jul 1998 A
5786578 Christy et al. Jul 1998 A
5800429 Edwards Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810809 Rydell Sep 1998 A
5836875 Webster, Jr. Nov 1998 A
5836897 Sakurai et al. Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5860951 Eggers Jan 1999 A
5860974 Abele Jan 1999 A
5860975 Goble et al. Jan 1999 A
5871469 Eggers et al. Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5873877 McGaffigan Feb 1999 A
5885277 Korth Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5902272 Eggers et al. May 1999 A
5944715 Goble et al. Aug 1999 A
5954716 Sharkey et al. Sep 1999 A
5964786 Ochs et al. Oct 1999 A
6004319 Goble et al. Dec 1999 A
6013076 Goble et al. Jan 2000 A
6015406 Goble et al. Jan 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6039734 Goble et al. Mar 2000 A
6047700 Eggers et al. Apr 2000 A
6056746 Goble et al. May 2000 A
6063079 Hovda et al. May 2000 A
6066134 Eggers et al. May 2000 A
6066489 Fields et al. May 2000 A
6068628 Fanton et al. May 2000 A
6074386 Goble et al. Jun 2000 A
6086585 Hovda et al. Jul 2000 A
6090106 Goble et al. Jul 2000 A
6090107 Borgmeier et al. Jul 2000 A
6093186 Goble et al. Jul 2000 A
6102046 Weinstein et al. Aug 2000 A
6103298 Edelson et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6117109 Eggers et al. Sep 2000 A
6126682 Sharkey et al. Oct 2000 A
6135999 Fanton et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6156334 Meyer-Ingold et al. Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6162217 Kannenberg et al. Dec 2000 A
6168593 Sharkey et al. Jan 2001 B1
6174309 Wrublewski et al. Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6197021 Panescu et al. Mar 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210405 Goble et al. Apr 2001 B1
6217574 Webster Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228078 Eggers May 2001 B1
6228081 Goble May 2001 B1
6234178 Goble et al. May 2001 B1
6235020 Cheng et al. May 2001 B1
6237604 Burnside et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6241723 Heim et al. Jun 2001 B1
6249706 Sobota et al. Jun 2001 B1
6254600 Willink et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6261286 Goble et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277112 Underwood et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6306134 Goble et al. Oct 2001 B1
6308089 von der Rur et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6319007 Livaditis Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6346104 Daly et al. Feb 2002 B2
6346107 Cucin Feb 2002 B1
6355032 Hovda et al. Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6364877 Goble et al. Apr 2002 B1
6379350 Sharkey et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6409722 Hoey et al. Jun 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416509 Goble et al. Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6440129 Simpson Aug 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468275 Wampler et al. Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6500173 Underwood et al. Dec 2002 B2
6514248 Eggers et al. Feb 2003 B1
6514250 Jahns et al. Feb 2003 B1
6517498 Burbank et al. Feb 2003 B1
6530922 Cosman Mar 2003 B2
6558382 Jahns et al. May 2003 B2
6565560 Goble et al. May 2003 B1
6578579 Burnside Jun 2003 B2
6589237 Woloszko et al. Jul 2003 B2
6602248 Sharps et al. Aug 2003 B1
6620156 Garito et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6635034 Cosmescu Oct 2003 B1
6640128 Vilsmeier et al. Oct 2003 B2
6656177 Truckai et al. Dec 2003 B2
6663554 Babaev Dec 2003 B2
6663627 Francischelli et al. Dec 2003 B2
6702810 McClurken et al. Mar 2004 B2
6730080 Harano et al. May 2004 B2
6746447 Davison et al. Jun 2004 B2
6749604 Eggers et al. Jun 2004 B1
6749608 Garito et al. Jun 2004 B2
D493530 Reschke Jul 2004 S
6770071 Woloszko et al. Aug 2004 B2
6780178 Palanker et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6780184 Tanrisever Aug 2004 B2
6802842 Ellman et al. Oct 2004 B2
6805130 Tasto et al. Oct 2004 B2
6830558 Flaherty et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6855143 Davison et al. Feb 2005 B2
6864686 Novak et al. Mar 2005 B2
6866671 Tierney et al. Mar 2005 B2
6872183 Sampson et al. Mar 2005 B2
6878149 Gatto Apr 2005 B2
6890307 Kokate et al. May 2005 B2
6892086 Russell May 2005 B2
6911027 Edwards et al. Jun 2005 B1
6920883 Bessette et al. Jul 2005 B2
6921398 Carmel et al. Jul 2005 B2
6929640 Underwood et al. Aug 2005 B1
6949096 Davison et al. Sep 2005 B2
6953461 McClurken et al. Oct 2005 B2
6960204 Eggers et al. Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6979601 Marr et al. Dec 2005 B2
6984231 Goble et al. Jan 2006 B2
6986770 Hood Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7001382 Gallo Feb 2006 B2
7004941 Tvinnereim et al. Feb 2006 B2
7010353 Gan et al. Mar 2006 B2
7041102 Truckai et al. May 2006 B2
7070596 Woloszko et al. Jul 2006 B1
7090672 Underwood et al. Aug 2006 B2
7094215 Davison et al. Aug 2006 B2
7094231 Ellman et al. Aug 2006 B1
7104986 Hovda et al. Sep 2006 B2
7131969 Hovda et al. Nov 2006 B1
7169143 Eggers et al. Jan 2007 B2
7179255 Lettice et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192428 Eggers et al. Mar 2007 B2
7201750 Eggers et al. Apr 2007 B1
7217268 Eggers et al. May 2007 B2
7241293 Davison Jul 2007 B2
7247155 Hoey et al. Jul 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7270659 Hovda et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7271363 Lee et al. Sep 2007 B2
7276061 Schaer et al. Oct 2007 B2
7276063 Davison et al. Oct 2007 B2
7278994 Goble Oct 2007 B2
7282048 Goble et al. Oct 2007 B2
7297143 Woloszko et al. Nov 2007 B2
7297145 Ormsby et al. Nov 2007 B2
7318823 Sharps et al. Jan 2008 B2
7331956 Hovda et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7344532 Goble et al. Mar 2008 B2
7357798 Sharps et al. Apr 2008 B2
7387625 Hovda et al. Jun 2008 B2
7419488 Ciarrocca et al. Sep 2008 B2
7429260 Underwood et al. Sep 2008 B2
7429262 Woloszko et al. Sep 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7527624 Dubnack et al. May 2009 B2
7678069 Baker et al. Mar 2010 B1
7691101 Davison et al. Apr 2010 B2
7699830 Martin Apr 2010 B2
7785322 Penny et al. Aug 2010 B2
7824398 Woloszko et al. Nov 2010 B2
7862560 Marion Jan 2011 B2
7887538 Bleich et al. Feb 2011 B2
7985072 Belikov et al. Jul 2011 B2
D658760 Cox et al. May 2012 S
8192424 Woloszko Jun 2012 B2
8303583 Hosier et al. Nov 2012 B2
8568405 Cox et al. Oct 2013 B2
8574187 Marion Nov 2013 B2
8685018 Cox et al. Apr 2014 B2
8747399 Woloszko et al. Jun 2014 B2
20010025177 Woloszko et al. Sep 2001 A1
20020029036 Goble et al. Mar 2002 A1
20020183739 Long Dec 2002 A1
20030013986 Saadat Jan 2003 A1
20030028189 Woloszko et al. Feb 2003 A1
20030088245 Woloszko et al. May 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030167035 Flaherty et al. Sep 2003 A1
20030171743 Tasto et al. Sep 2003 A1
20030208194 Hovda et al. Nov 2003 A1
20030208196 Stone Nov 2003 A1
20030212396 Eggers et al. Nov 2003 A1
20030216725 Woloszko et al. Nov 2003 A1
20030216726 Eggers et al. Nov 2003 A1
20030216732 Truckai et al. Nov 2003 A1
20030232048 Yang et al. Dec 2003 A1
20040030330 Brassell et al. Feb 2004 A1
20040049180 Sharps et al. Mar 2004 A1
20040058153 Ren et al. Mar 2004 A1
20040092925 Rizoiu et al. May 2004 A1
20040102044 Mao et al. May 2004 A1
20040116922 Hovda et al. Jun 2004 A1
20040127893 Hovda Jul 2004 A1
20040186418 Karashima Sep 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050004634 Hovda et al. Jan 2005 A1
20050010205 Hovda et al. Jan 2005 A1
20050033278 McClurken et al. Feb 2005 A1
20050119650 Sanders et al. Jun 2005 A1
20050131402 Ciarrocca et al. Jun 2005 A1
20050187543 Underwood et al. Aug 2005 A1
20050197657 Goth et al. Sep 2005 A1
20050234439 Underwood et al. Oct 2005 A1
20050245923 Christopherson et al. Nov 2005 A1
20050251134 Woloszko et al. Nov 2005 A1
20050261754 Woloszko et al. Nov 2005 A1
20050273091 Booth et al. Dec 2005 A1
20050288665 Woloszko et al. Dec 2005 A1
20060036237 Davison et al. Feb 2006 A1
20060095031 Ormsby May 2006 A1
20060097615 Tsakalakos et al. May 2006 A1
20060161148 Behnke Jul 2006 A1
20060161150 Keppel Jul 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060189971 Eggers et al. Aug 2006 A1
20060253117 Hovda et al. Nov 2006 A1
20060259025 Dahla Nov 2006 A1
20070010808 Dahla Jan 2007 A1
20070010809 Sanders et al. Jan 2007 A1
20070093800 Wham et al. Apr 2007 A1
20070106288 Woloszko et al. May 2007 A1
20070112348 Eggers et al. May 2007 A1
20070129715 Eggers et al. Jun 2007 A1
20070149966 Dahla et al. Jun 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070179495 Mitchell et al. Aug 2007 A1
20070179497 Eggers et al. Aug 2007 A1
20070208334 Woloszko et al. Sep 2007 A1
20070208335 Woloszko et al. Sep 2007 A1
20070213700 Davison et al. Sep 2007 A1
20070282323 Woloszko et al. Dec 2007 A1
20080004615 Woloszko et al. Jan 2008 A1
20080004621 Dahla et al. Jan 2008 A1
20080077128 Woloszko et al. Mar 2008 A1
20080138761 Pond Jun 2008 A1
20080140069 Filloux et al. Jun 2008 A1
20080154255 Panos et al. Jun 2008 A1
20080167645 Woloszko Jul 2008 A1
20080234674 McClurken et al. Sep 2008 A1
20080243116 Anderson Oct 2008 A1
20080261368 Ramin et al. Oct 2008 A1
20080300590 Horne et al. Dec 2008 A1
20090222001 Greeley Sep 2009 A1
20100042101 Inagaki et al. Feb 2010 A1
20100121317 Lorang et al. May 2010 A1
20100152726 Cadouri et al. Jun 2010 A1
20100228246 Marion Sep 2010 A1
20100292689 Davison et al. Nov 2010 A1
20100318083 Davison et al. Dec 2010 A1
20100324549 Marion Dec 2010 A1
20100331883 Schmitz et al. Dec 2010 A1
20110137308 Woloszko et al. Jun 2011 A1
20110208177 Brannan Aug 2011 A1
20110245826 Woloszko et al. Oct 2011 A1
20110270256 Nelson et al. Nov 2011 A1
20110319887 Keppel Dec 2011 A1
20120083782 Stalder et al. Apr 2012 A1
20120095453 Cox et al. Apr 2012 A1
20120095454 Cox et al. Apr 2012 A1
20120109123 Woloszko et al. May 2012 A1
20120196251 Taft et al. Aug 2012 A1
20120197344 Taft et al. Aug 2012 A1
20120215221 Woloszko Aug 2012 A1
20120296328 Marion Nov 2012 A1
20130116680 Woloszko May 2013 A1
20140018798 Cox et al. Jan 2014 A1
20140025065 Marion Jan 2014 A1
20140135760 Cadouri et al. May 2014 A1
20140155882 Cox et al. Jun 2014 A1
20140236141 Woloszko et al. Aug 2014 A1
20140257277 Woloszko et al. Sep 2014 A1
20140257278 Woloszko et al. Sep 2014 A1
20140257279 Woloszko et al. Sep 2014 A1
20140276725 Cox Sep 2014 A1
20150032101 Woloszko et al. Jan 2015 A1
Foreign Referenced Citations (78)
Number Date Country
3119735 Jan 1983 DE
3930451 Mar 1991 DE
69635311 Apr 2007 DE
10201003288 Sep 2014 DE
423757 Mar 1996 EP
0703461 Mar 1996 EP
0740926 Nov 1996 EP
0 754 437 Jan 1997 EP
0 694 290 Nov 2000 EP
1334699 Aug 2003 EP
1428480 Jun 2004 EP
1707147 Oct 2006 EP
2055254 Jan 2015 EP
2313949 Jan 1977 FR
467502 Jun 1937 GB
2160102 Dec 1985 GB
2299216 Sep 1996 GB
2 308 979 Jul 1997 GB
2 308 980 Jul 1997 GB
2 308 981 Jul 1997 GB
2 327 350 Jan 1999 GB
2 327 351 Jan 1999 GB
2 327 352 Jan 1999 GB
2333455 Jul 1999 GB
2406793 Apr 2005 GB
2514442 Nov 2014 GB
57-57802 Apr 1982 JP
57-117843 Jul 1982 JP
9003152 Apr 1990 WO
9007303 Jul 1990 WO
9221278 Dec 1992 WO
9313816 Jul 1993 WO
9320747 Oct 1993 WO
9404220 Mar 1994 WO
9408654 Apr 1994 WO
9410921 May 1994 WO
9426228 Nov 1994 WO
9534259 Dec 1995 WO
9600040 Jan 1996 WO
9600042 Jan 1996 WO
9639086 Dec 1996 WO
9700646 Jan 1997 WO
9700647 Jan 1997 WO
9718768 May 1997 WO
9724073 Jul 1997 WO
9724074 Jul 1997 WO
9724993 Jul 1997 WO
9724994 Jul 1997 WO
9743971 Nov 1997 WO
9748345 Dec 1997 WO
9748346 Dec 1997 WO
9807468 Feb 1998 WO
9826724 Jun 1998 WO
9827879 Jul 1998 WO
9827880 Jul 1998 WO
9856324 Dec 1998 WO
9920213 Apr 1999 WO
9951155 Oct 1999 WO
9951158 Oct 1999 WO
9956648 Nov 1999 WO
0000098 Jan 2000 WO
0009053 Feb 2000 WO
0062685 Oct 2000 WO
0124720 Apr 2001 WO
0187154 May 2001 WO
0195819 Dec 2001 WO
0236028 May 2002 WO
02102255 Dec 2002 WO
03024305 Mar 2003 WO
03092477 Nov 2003 WO
2004026150 Apr 2004 WO
2004071278 Aug 2004 WO
2005125287 Dec 2005 WO
2007006000 Jan 2007 WO
2007056729 May 2007 WO
2010052717 May 2010 WO
2012050636 Apr 2012 WO
2012050637 Apr 2012 WO
Non-Patent Literature Citations (112)
Entry
Buchelt, et al. “Excimer Laser Ablation of Fibrocartilage: An In Vitro and In Vivo Study”, Lasers in Surgery and Medicine, vol. 11, pp. 271-279, 1991.
Costello et al., “Nd: YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy”, Lasers in Surgery and Medicine, vol. 12, pp. 121-124, 1992.
Rand et al., “Effect of Elecctrocautery on Fresh Human Articular Cartilage”, J. Arthro. Surg., vol. 1, pp. 242-246, 1985.
O'Neill et al., “Percutaneous Plasma Discectomy Stimulates Repair in Injured Porcine Intervertebral Discs”, Dept. of Orthopaedic Surgery, Dept. of Radiology University of California at San Francisco, CA, 3 pgs.
PCT International Search Report for PCT/US99/14685), 1 pg Mailed Oct. 21, 1999.
PCT Notification of International Preliminary Examination Report for PCT/US99/14685, 4 pgs, Mailed Feb. 20, 2001.
PCT International Search Report for PCT/US98/22323, 1 pg, Mailed Mar. 3, 1999.
PCT Notification of International Preliminary Examination Report for PCT/US98/22323, 5 pgs, Mailed Nov. 28, 2000.
European Search Report for EP 98953859, 2 pgs, Jul. 2, 2001.
Supplementary European Search Report for EP 98953859, 3 pgs, Oct. 18, 2001.
PCT International Search Report for PCT/US99/18289, 1 pg, Mailed Dec. 7, 1999.
PCT Notification of International Preliminary Examination Report for PCT/US99/18289, 4 pgs, Mailed Jul. 7, 2000.
European Search Report for EP 99945039.8, 3 pgs, Oct. 1, 2001.
PCT International Search Report for PCT/US02/19261, 1 pg, Mailed Sep. 18, 2002.
PCT International Preliminary Examination Report for PCT/US02/19261, 3 pgs, Mar. 25, 2003.
PCT International Search Report for PCT/US02/29476, 1 pg, Mailed May 24, 2004.
PCT International Search Report for PCT/US03/13686, 1 pg, Mailed Nov. 25, 2003.
PCT International Search Report for PCT/USO4/03614, 1 pg, Mailed Sep. 14, 2004.
PCT Written Opinion of the International Searching Authority for PCT/US04/03614, 4 pgs, Mailed Sep. 14, 2004.
EP Communication, European Examination Report for EP 98953859.0, 3 pgs, Jun. 14, 2004.
EP Communication, European Examination Report for EP 99945039.8, 5 pgs, May 10, 2004.
PCT Notification of International Search Report and Written Opinion for PCT/US06/26321, 8pgs, Mailed Apr. 25, 2007.
PCT Notification of the International Search Report and Written Opinion for PCT/US06/60618, 7pgs, Mailed Oct. 5, 2007.
Barry et al., “The Effect of Radiofrequency-generated Thermal Energy on the Mechanical and Histologic Characteristics of the Arterial Wall in Vivo: Implications of Radiofrequency Angioplasty” American Heart Journal vol. 117, pp. 332-341, 1982.
Codman & Shurtleff, Inc. “The Malis Bipolar Coagulating and Bipolar Cutting System CMC-II” brochure, early, 2 pgs, 1991.
Codman & Shurtleff, Inc. “The Malis Bipolar Electrosurgical System CMC-III Instruction Manual” , 15 pgs, Jul. 1991.
Cook et al., “Therapeutic Medical Devices: Application and Design” , Prentice Hall, Inc., 3pgs, 1982.
Dennis et al. “Evolution of Electrofulguration in Control of Bleeding of Experimental Gastric Ulcers,” Digestive Diseases and Sciences, vol. 24, No. 11, 845-848, Nov. 1979.
Dobbie, A.K., “The Electrical Aspects of Surgical Diathermy, Bio Medical Engineering” Bio-Medical Engineering vol. 4, pp. 206-216, May 1969.
Elsasser, V.E. et al., “An Instrument for Transurethral Resection without Leakage of Current” Acta Medicotechnica vol. 24, No. 4, pp. 129-134, 1976.
Geddes, “Medical Device Accidents: With Illustrative Cases” CRC Press, 3 pgs, 1998.
Honig, W., “The Mechanism of Cutting in Electrosurgery” IEEE pp. 58-65, 1975.
Kramolowsky et al. “The Urological App of Electorsurgery” J. of Urology vol. 146, pp. 669-674, 1991.
Kramolowsky et al. “Use of 5F Bipolar Electrosurgical Probe in Endoscopic Urological Procedures” J. of Urology vol. 143, pp. 275-277, 1990.
Lee, B et al. “Thermal Compression and Molding of Artherosclerotic Vascular Tissue with Use” JACC vol. 13(5), pp. 1167-1171, 1989.
Letter from Department of Health to Jerry Malis dated Jan. 24, 1991, 3 pgs.
Letter from Department of Health to Jerry Malis dated Jul. 25, 1985, 1 pg.
Letter from Jerry Malis to FDA dated Jul. 25, 1985, 2 pgs.
Lu, et al., “Electrical Thermal Angioplasty: Catheter Design Features, In Vitro Tissue Ablation Studies and In Vitro Experimental Findings,” Am J. Cardiol vol. 60, pp. 1117-1122, Nov. 1, 1987.
Malis, L., “Electrosurgery, Technical Note,” J. Neursurg., vol. 85, pp. 970-975, Nov. 1996.
Malis, L., “Excerpted from a seminar by Leonard I. Malis, M.D. at the 1995 American Association of Neurological Surgeons Meeting,” 1pg, 1995.
Malis, L., “Instrumentation for Microvascular Neurosurgery” Cerebrovascular Surgery, vol. 1, pp. 245-260, 1985.
Malis, L., “New Trends in Microsurgery and Applied Technology,” Advanced Technology in Neurosurgery, pp. 1-16, 1988.
Malis, L., “The Value of Irrigation During Bipolar Coagulation” See ARTC 21602, 1 pg, Apr. 9, 1993.
Nardella, P.C., SPIE 1068: pp. 42-49, Radio Frequency Energy and Impedance Feedback, 1989.
O'Malley, Schaum's Outline of Theory and Problems of Basic Circuit Analysis, McGraw-Hill, 2nd Ed., pp. 3-5, 1992.
Olsen MD, Bipolar Laparoscopic Cholecstectomy Lecture (marked confidential), 12 pgs, Oct. 7, 1991.
Pearce, John A. “Electrosurgery”, pp. 17, 69-75, 87, John Wiley & Sons, New York, 1986.
Pearce, John A., “Electrosurgery”, Handbook of Biomedical Engineering, chapter 3, Academic Press Inc., N.Y., pp. 98-113, 1988.
Piercey et al., “Electrosurgical Treatment of Experimental Bleeding Canine Gastric Ulcers” Gastroenterology vol. 74(3), pp. 527-534, 1978.
Protell et al., “Computer-Assisted Electrocoagulation: Bipolar v. Monopolar in the Treatment of Experimental Canine Gastric Ulcer Bleeding,” Gastroenterology vol. 80, No. 3, pp. 451-455, 1981.
Ramsey et al., “A Comparison of Bipolar and Monopolar Diathermy Probes in Experimental Animals”, Urological Research vol. 13, pp. 99-102, 1985.
Selikowitz et al., “Electric Current and Voltage Recordings on the Myocardium During Electrosurgical Procedures in Canines,” Surgery, Gynecology & Obstetrics, vol. 164, pp. 219-224, Mar. 1987.
Shuman, “Bipolar Versus Monopolar Electrosurgery: Clinical Applications,” Dentistry Today, vol. 20, No. 12, 7 pgs, Dec. 2001.
Slager et al. “Spark Erosion of Arteriosclerotic Plaques” Z. Kardiol. 76:Suppl. 6, pp. 67-71, 1987.
Slager et al. “Vaporization of Atherosclerotice Plaques by Spark Erosion” JACC 5(6): pp. 1382-1386, Jun. 1985.
Stoffels, E. et al., “Investigation on the Interaction Plasma-Bone Tissue”, E-MRS Spring Meeting, 1 pg, Jun. 18-21, 2002.
Stoffels, E. et al., “Biomedical Applications of Plasmas”, Tutorial presented prior to the 55th Gaseous Electronics Conference in Minneapolis, MN, 41 pgs, Oct. 14, 2002.
Stoffels, E. et al., “Plasma Interactions with Living Cells”, Eindhoven University of Technology, 1 pg, 2002.
Stoffels, E. et al., “Superficial Treatment of Mammalian Cells using Plasma Needle”, J. Phys. D: Appl. Phys. 26, pp. 2908-2913, Nov. 19, 2003.
Stoffels, E. et al., “Plasma Needle”, Eindhoven University of Technology, 1 pg, Nov. 28, 2003.
Stoffels, E. et al., “Plasma Physicists Move into Medicine”, Physicsweb, 1 pg, Nov. 2003.
Stoffels, E. et al., “Plasma Treated Tissue Engineered Skin to Study Skin Damage”, Biomechanics and Tissue Engineering, Materials Technology, 1 pg, 2003.
Stoffels, E. et al., “Plasma Treatment of Dental Cavities: A Feasibility Study”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1540-1542, Aug. 2004.
Stoffels, E. et al., “The Effects of UV Irradiation and Gas Plasma Treatment on Living Mammalian Cells and Bacteria: A Comparative Approach”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1544-1550 Aug. 2004.
Stoffels, E. et al., “Electrical and Optical Characterization of the Plasma Needle”, New Journal of Physics 6, pp. 1-14, Oct. 28, 2004.
Stoffels, E. et al., “Where Plasma Meets Plasma”, Eindhoven University of Technology, 23 pgs, 2004.
Stoffels, E. et al., “Gas Plasma effects on Living Cells”, Physica Scripta, T107, pp. 79-82, 2004.
Stoffels, E. et al., “Plasma Treatment of Mammalian Vascular Cells: A Quantitative Description”, IEEE Transaction on Plasma Science, vol. 33, No. 2, pp. 771-775, Apr. 2005.
Stoffels, E. et al., “Deactivation of Escherichia coli by the Plasma Needle”, J. Phys. D: Appl. Phys. 38, pp. 1716-1721, May 20, 2005.
Stoffels, E. et al., “Development of a Gas Plasma Catheter for Gas Plasma Surgery”, XXVIIth ICPIG, Endoven University of Technology, pp. 18-22, Jul. 2005.
Stoffels, E. et al., “Development of a Smart Positioning Sensor for the Plasma Needle”, Plasma Sources Sci. Technol. 15, pp. 582-589, Jun. 27, 2006.
Stoffels, E. et al., Killing of S. Mutans Bacteria Using a Plasma Needle at Atmospheric Pressure, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1317-1324, Aug. 2006.
Stoffels, E. et al., “Plasma-Needle Treatment of Substrates with Respect to Wettability and Growth of Excherichia coli and Streptococcus mutans”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1325-1330, Aug. 2006.
Stoffels, E. et al., “Reattachment and Apoptosis after Plasma-Needle Treatment of Cultured Cells”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1331-1336, Aug. 2006.
Stoffels, E. et al., “UV Excimer Lamp Irradiation of Fibroblasts: The Influence on Antioxidant Homostasis”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1359-1364, Aug. 2006.
Stoffels, E. et al., “Plasma Needle for In Vivo Medical Treatment: Recent Developments and Perspectives”, Plasma Sources Sci. Technol. 15, pp. S169-S180, Oct. 6, 2006.
Swain, C.P., et al., “Which Electrode, A Comparison of four endoscopic methods of electrocoagulation in experimental bleeding ulcers” Gut vol. 25, pp. 1424-1431, 1987.
Tucker, R. et al. “A Comparison of Urologic Application of Bipolar Versus Monopolar Five French Electrosurgical Probes” J. of Urology vol. 141, pp. 662-665, 1989.
Tucker, R. et al. “In vivo effect of 5 French Bipolar and Monopolar Electrosurgical Probes on the Porcine Bladder” Urological Research vol. 18, pp. 291-294, 1990.
Tucker, R. et al., “Demodulated Low Frequency Currents from Electrosurgical Procedures,” Surgery, Gynecology and Obstetrics, 159:39-43, 1984.
Tucker, R. et al., Abstract P14-11, p. 248, “A Bipolar Electrosurgical Turp Loop”, Nov. 1989.
Valley Forge Scientific Corp., “Summary of Safety and Effective Information from 510K”, 2pgs, 1991.
Valley Forge's New Products, CLINICA, 475, 5, Nov. 6, 1991.
Valleylab SSE2L Instruction Manual, 11 pgs, Jan. 6, 1983.
Valleylab, Inc. “Valleylab Part No. 945 100 102 A” Surgistat Service Manual, pp. 1-46, Jul. 1988.
Wattiez, Arnaud et al., “Electrosurgery in Operative Endoscopy,” Electrosurgical Effects, Blackwell Science, pp. 85-93, 1995.
Wyeth, “Electrosurgical Unit” pp. 1181-1202, 2000.
UK Search Report for GB0805062.7 1 pg, Jul. 16, 2008.
BiLAP IFU 910033-002 Rev A for BiLAP Model 3527, L-Hook; BiLAP Model 3525, J-Hook; BiLAP Model 3529, High Angle, 2 pgs, Nov. 30, 1993.
BiLAP IFU 910026-001 Rev A for BiLAP Model 3525, J-Hook, 4 pgs, May 20, 1991.
BiLAP Generator Settings, Jun. 1991.
Tucker et al. “The interaction between electrosurgical generators, endroscopic electrodes, and tissue,” Gastrointestinal Endoscopy, vol. 38, No. 2, pp. 118-122, 1992.
European Examination Report for EP 02749601.7 4pgs, Dec. 2, 2009.
European Examination Report 2 for EP 04708664 5pgs, May 3, 2010.
Extended European Search Report for EP09152846, 8pgs, Jan. 5, 2010.
European Search Report for EP 09152850, 2 pgs, Dec. 29, 2009.
European Examination Report for EP 02773432 4 pgs, Sep. 22, 2009.
European Examination Report for EP 05024974 4 pgs, Dec. 5, 2008.
European Examination Report for EP 04708664 7pgs, Sep. 7, 2009.
European Search Report for EP 02773432 3pgs, Dec. 19, 2008.
European Search Report for EP 04708664.0 5pgs, Apr. 6, 2009.
UK Search Report for GB0800129.9 2pgs, May 8, 2008.
UK Search Report for GB0900604.0 4 pgs, May 15, 2009.
UK Search Report for GB1110342.1 3pgs, Oct. 18, 2011.
uropean Examination Report (3rd) for EP 04708664 6pgs Nov. 6, 2012.
UK Suppl Search Report for GB1110342.1 2pgs Aug. 16, 2012.
UK Combined Search and Exam Report for GB1403997.8 5pgs Sep. 17, 2014.
Elgrabli, D., Abella-Gallart, S., Aguerre-Chariol, O., Robidel F.R., Boczkowski, J., Lacroix, G. (2007). Effect of BSA on carbon nanotube dispersion in vivi and in vitro studies. vol. 1, No. 4, pp. 266-278, 2007.
“Work functions for photoelectric effect”. (2001). Retrieved on Jun. 11, 2014 from http://hyperphysics.phyastr.gsu.edu/hbase/tables/photoelec.html, 2001.
Jing et al. (2007). Biocompatibility of Cerium Oxide Films Synthesized by Dual Plasma Deposition. Key Enginerring Materials. vol. 330-332.pp. 749-752, 2007.
Wikipedia Field Electron Emission. Retrieved on Dec. 29, 2014 from http://en.wikipedia.org/wiki/Field—electron—emission.
Related Publications (1)
Number Date Country
20090209956 A1 Aug 2009 US